Uterine leiomyomas, or fibroids, are the most common benign tumor in reproductive aged women. Affected women may remain asymptomatic or may report symptoms related to abnormal uterine bleeding, infertility, or pelvic pain and pressure. Depending on a patient's symptomatology and reproductive plans, treatment options include expectant management, medical management (hormonal and non-hormonal), or surgical management (myomectomy or hysterectomy). In those wishing to defer surgical management, non-hormonal therapies such as non-steroidal anti-inflammatory drugs and tranexamic acid have been shown to decrease menstrual blood loss. In patients with more symptomatic leiomyomas, hormonal therapies such as gonadotropin-releasing hormone agonists and selective progesterone receptor modulators are effective at reducing leiomyoma volume, uterine size, and menstrual blood loss. This manuscript will detail the available and emerging hormonal and non-hormonal treatments for symptomatic uterine leiomyomas.

Kashani, B.N., Centini, G., Morelli, S.S., Weiss, G., Petraglia, F. (2016). Role of Medical Management for Uterine Leiomyomas. BAILLIERE'S BEST PRACTICE & RESEARCH. CLINICAL OBSTETRICS & GYNAECOLOGY, 34, 85-103 [10.1016/j.bpobgyn.2015.11.016].

Role of Medical Management for Uterine Leiomyomas

Centini, Gabriele;
2016-01-01

Abstract

Uterine leiomyomas, or fibroids, are the most common benign tumor in reproductive aged women. Affected women may remain asymptomatic or may report symptoms related to abnormal uterine bleeding, infertility, or pelvic pain and pressure. Depending on a patient's symptomatology and reproductive plans, treatment options include expectant management, medical management (hormonal and non-hormonal), or surgical management (myomectomy or hysterectomy). In those wishing to defer surgical management, non-hormonal therapies such as non-steroidal anti-inflammatory drugs and tranexamic acid have been shown to decrease menstrual blood loss. In patients with more symptomatic leiomyomas, hormonal therapies such as gonadotropin-releasing hormone agonists and selective progesterone receptor modulators are effective at reducing leiomyoma volume, uterine size, and menstrual blood loss. This manuscript will detail the available and emerging hormonal and non-hormonal treatments for symptomatic uterine leiomyomas.
2016
Kashani, B.N., Centini, G., Morelli, S.S., Weiss, G., Petraglia, F. (2016). Role of Medical Management for Uterine Leiomyomas. BAILLIERE'S BEST PRACTICE & RESEARCH. CLINICAL OBSTETRICS & GYNAECOLOGY, 34, 85-103 [10.1016/j.bpobgyn.2015.11.016].
File in questo prodotto:
File Dimensione Formato  
Role of Medical Management for Uterine Leiomyomas.pdf

non disponibili

Tipologia: PDF editoriale
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 409.95 kB
Formato Adobe PDF
409.95 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Role of medical management PostPrint.pdf

accesso aperto

Descrizione: http://dx.doi.org/10.1016/j.bpobgyn.2015.11.016
Tipologia: Post-print
Licenza: Creative commons
Dimensione 254.37 kB
Formato Adobe PDF
254.37 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/1031597